EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target

EyePoint faces clinical, commercial hurdles despite DME, AMD progress and solid funding through 2027. Read why EYPT stock is ...

Chord Energy: A Deeply Undervalued Cash Flow Machine With Significant Potential

Chord Energy (CHRD) is a strong buy with robust financials, high yields, and growth amid oil market pressures. See here for ...